Desvenlafaxine: study card

Desvenlafaxine — SNRI antidepressant. Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name
Desvenlafaxine
Class
SNRI antidepressant
Mechanism
Thought to potentiate serotonin and norepinephrine in the CNS by inhibiting their reuptake; a potent, selective SNRI.
Used for
Major depressive disorder (adults)
Common side effects
Nausea; Dizziness; Insomnia; Hyperhidrosis; Constipation
Boxed warning
Antidepressants increased suicidal thoughts and behaviors in children, adolescents, and young adults; monitor closely for worsening.
Warnings
Serotonin syndrome; Elevated blood pressure; Increased bleeding risk
Interactions
MAO inhibitors (contraindicated); Other serotonergic drugs; Aspirin, NSAIDs, anticoagulants

Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.

Drug class families: Serotonin-norepinephrine reuptake inhibitors

Read the source label ↗

Label date: 20260724 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Pronunciation

Desvenlafaxine: des-VEN-la-fax-een

Pronunciation is shown for the US English generic name.

Other drugs in the same class

Serotonin-norepinephrine reuptake inhibitors: Duloxetine, Venlafaxine

Body system

Psychiatry · 30 Drug cards

Compare with related cards

Duloxetine

Same class family: Serotonin-norepinephrine reuptake inhibitors

Mechanism: Exact mechanism unknown; believed to potentiate serotonergic and noradrenergic activity in the CNS.

On both cards: Common side effects — Nausea; Hyperhidrosis; Constipation · Warnings — Serotonin syndrome

Only on the Duloxetine card: Used for — Major depressive disorder in adults; Generalized anxiety disorder in adults and children aged 7 years and older; Diabetic peripheral neuropathic pain in adults; Fibromyalgia in adults and adolescents aged 13 years and older; Chronic musculoskeletal pain in adults · Common side effects — Dry mouth; Somnolence · Warnings — Hepatotoxicity; Orthostatic hypotension, falls, syncope · Interactions — Potent CYP1A2 inhibitors; Potent CYP2D6 inhibitors; MAOIs

Venlafaxine

Same class family: Serotonin-norepinephrine reuptake inhibitors

Mechanism: Thought to potentiate serotonin and norepinephrine in the CNS by inhibiting their reuptake.

On both cards: Common side effects — Nausea · Warnings — Serotonin syndrome; Elevated blood pressure · Interactions — Other serotonergic drugs

Only on the Venlafaxine card: Used for — Major depressive disorder in adults; Generalized anxiety disorder in adults; Social anxiety disorder in adults; Panic disorder in adults · Common side effects — Somnolence; Dry mouth; Sweating; Abnormal ejaculation · Warnings — Discontinuation syndrome · Interactions — MAO inhibitors; Antiplatelets / anticoagulants

Sertraline

Same body system: Psychiatry

Mechanism: Potentiates serotonergic activity in the CNS by inhibiting neuronal reuptake of serotonin (5-HT).

On both cards: Common side effects — Nausea; Hyperhidrosis · Warnings — Serotonin syndrome

Only on the Sertraline card: Used for — Major depressive disorder in adults; Obsessive-compulsive disorder in adults and children aged 6–17 years; Panic disorder, PTSD or social anxiety disorder in adults; Premenstrual dysphoric disorder in adults · Common side effects — Diarrhea / loose stool; Tremor; Ejaculation failure · Warnings — Increased risk of bleeding; Activation of mania / hypomania · Interactions — MAOIs (incl. linezolid, IV methylene blue); Pimozide; Warfarin and other protein-bound drugs

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.

Boxed warnings on related cards

Duloxetine: Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents and young adults.

Venlafaxine: Antidepressants increased suicidal thoughts and behaviors in pediatric and young adult patients; not approved in children.